<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 1998
LASERSCOPE
(Exact name of Registrant as specified in its charter)
CALIFORNIA 0-18053 77-0049527
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
3052 ORCHARD DRIVE
SAN JOSE, CALIFORNIA 95134-2011
(Address of principal executive offices) (Zip code)
(408) 943-0636
(Registrant's telephone number, including area code)
<PAGE> 2
Item 2. Other Events.
On May 7, 1998, Heraeus Med GmbH ("Heraeus Med") sold 4,268,345 shares of
Laserscope common stock, constituting all the shares of Laserscope common stock
held by Heraeus Med, to certain investors (the "Investors") in a private
placement transaction (the "Private Placement"). In connection with the Private
Placement, Laserscope agreed to register with the Securities and Exchange
Commission, prior to June 7, 1998, the shares acquired from Heraeus Med by the
Investors. In addition, on April 29, 1998, Laserscope's Board of Directors
approved the Private Placement and related matters, excluding these transactions
from the application of (a) Laserscope's Common Shares Rights Agreement dated as
of October 31, 1996, as amended, (b) Laserscope's management continuity
agreements with certain of its executive officers and (c) the standstill
provisions of the Heraeus Agreement (as defined below).
Under the terms of an agreement dated April 22, 1996 (the "Heraeus Agreement")
between Heraeus and Laserscope, Laserscope agreed to use its best efforts to
elect nominees of Heraeus Med to Laserscope's Board of Directors provided
Heraeus Med held specified amounts of Laserscope Common Stock. Specifically, the
Heraeus Agreement obligated the Company to use its best efforts to have three
nominees of Heraeus Med elected to the Board of Directors so long as Heraeus Med
owns at least 3.3 million shares of Laserscope's Common Stock, two nominees of
Heraeus Med elected to the Board of Directors so long as Heraeus Med owns at
least 1.6 million shares of Laserscope Common Stock and one nominee of Heraeus
Med so long as Heraeus Med owns at least 600,000 shares of Laserscope Common
Stock. Messrs. David Cohen, Klaus Goffloo and Thomas Ihlenfeldt were the Heraeus
Med nominees (the "Heraeus Directors") to the Laserscope Board of Directors. As
a result of the Private Placement, Heraeus Med no longer holds shares of
Laserscope Common Stock and Laserscope no longer is obligated to nominate
Heraeus designees to the Laserscope Board of Directors. On May 7, 1998, in
connection with the consummation of the Private Placement, Messrs. Cohen,
Goffloo and Ihlenfeldt resigned from Laserscope's Board of Directors. In
connection with such resignations, Laserscope's Board, pursuant to the Company's
Bylaws, reduced the number of Laserscope directors from eight to five.
A copy of the press release of Laserscope dated May 11, 1998, related to the
above described transactions is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press Release of Laserscope dated May 11, 1998
99.2 Letter Agreement dated as of May 7, 1998 by and among
Laserscope and the parties named therein.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
LASERSCOPE
(Registrant)
Dated: May 15, 1998 By: /s/ DENNIS LALUMANDIERE
-----------------------------------------
Dennis LaLumandiere
Vice President of Finance and
Chief Financial Officer
<PAGE> 4
EXHIBIT INDEX
Exhibit Number
99.1 Press Release of Laserscope dated May 11, 1998
99.2 Letter Agreement dated as of May 7, 1998 by and among Laserscope and the
parties named therein.
<PAGE> 1
EXHIBIT 99.1
LASERSCOPE ANNOUNCED THAT HERAEUS MED
HAS SOLD ITS OWNERSHIP POSITION IN LASERSCOPE
TO GROUP OF INSTITUTIONAL INVESTORS
SAN JOSE, Calif., May 12, 1998 -- Laserscope (Nasdaq:LSCP) announced today that
on Monday, May 11, 1998, Heraeus Med GmbH, the Company's largest shareholder,
entered into a series of agreements whereby it sold all of its 4,268,345 shares
of Laserscope common stock in an unregistered private sale to a limited number
of accredited investors, predominately institutional purchasers. Heraeus Med is
a subsidiary of Heraeus Holding GmbH, a privately held company based in Hanau,
Germany.
Laserscope has agreed to file a registration statement with the U.S.
Securities and Exchange Commission (SEC) covering the resale of the shares by
the investors. Until registered, the shares may not be resold without an
exemption from the registration requirements of the Securities Act of 1933, as
amended.
In connection with the Heraeus Med sale, David Cohen, Thomas Ihlenfeldt
and Klaus Goffloo, Laserscope directors designated by Heraeus Med, resigned from
Laserscope's Board of Directors as contemplated under agreements between Heraeus
Med and Laserscope.
Laserscope designs, manufactures, sells and services on a worldwide
basis an advanced line of medical laser systems and related energy delivery
devices for the office, outpatient surgical center and hospital markets. The
Company is a pioneer in the development and commercialization of lasers and
advanced fiberoptic devices for a wide variety of applications, including
photoselective medicine to treat cancer and other diseases.
Statements in this announcement about future results are preliminary and
based on partial information and assumptions, and actual results may differ.
Except for the historical information presented, the matters discussed in this
announcement contain forward-looking statements that involve risks and
uncertainties. These risks and uncertainties are detailed from time to time in
the Company's public disclosure filings with the U.S. Securities and Exchange
Commission. Copies of Laserscope's most recent Forms 10K and 10Q are available
upon request from its Investor Relations Department.
<PAGE> 1
EXHIBIT 99.2
LASERSCOPE
3052 Orchard Drive
San Jose, California, U.S.A. 95134-2011
May 7, 1998
To the Investors
Listed on Exhibit A hereto
Registration Rights
Dear Investor:
This letter shall constitute our agreement (the "Agreement") concerning
certain registration rights in connection with your purchase of certain shares
of Laserscope Common Stock from Heraeus Med GmbH ("Heraeus Med") pursuant to the
Stock Purchase Agreement (the "Purchase Agreement") among the Investors and
Heraeus Med attached as EXHIBIT B hereto (collectively, the "Investors").
A. Laserscope, a publicly traded California corporation, is a
manufacturer and seller of multi-specialty hospital and physician office-based
laser surgical systems and accessories. In August of 1996, Laserscope and
Heraeus Med consummated an acquisition transaction pursuant to which Laserscope
acquired Heraeus Surgical, Inc., a wholly-owned subsidiary of Heraeus Med as
well as certain other assets and liabilities (the "Heraeus Assets"). As
consideration for the Heraeus Assets, and pursuant to the acquisition agreement
(the "Heraeus Agreement"), Laserscope issued to Heraeus Med 4,609,345 shares of
Laserscope's Common Stock (the "Laserscope Shares"), of which 500,000 Laserscope
Shares were placed in escrow pursuant to the terms of the Acquisition Agreement.
Pursuant to the Heraeus Agreement, Laserscope provided Heraeus certain
registration rights.
B. Pursuant to the terms of the Purchase Agreement, Heraeus desires
to sell and the Investors desire to purchase those Laserscope Shares not
previously transferred by Heraeus, in the amounts and on the terms and
conditions set forth therein.
C. To facilitate the consummation of the transactions contemplated
in the Purchase Agreement, Laserscope agrees to provide to the Investors certain
registration rights on the terms and conditions set forth below.
<PAGE> 2
AGREEMENT
Registration Rights
1.1 Certain Definitions. The following terms shall have the
following respective meanings:
"Commission" shall mean the United States Securities and
Exchange Commission.
"Company" shall mean Laserscope, a California corporation.
"Common Shares" shall mean the shares of the Company's Common
Stock acquired by the Investors pursuant to the Purchase Agreement.
"Registration Expenses" shall mean all expenses incurred by the
Company in complying with Section 1.4 hereof, including, without limitation, all
registration, qualification and filing fees, printing expenses, escrow fees,
fees and disbursements of counsel for the Company, blue sky fees and expenses.
"Restricted Securities" shall mean the securities of the Company
required to bear the legend set forth in Section 1.3 herein.
"Securities Act" shall mean the United States Securities Act of
1933, as amended and the rules and regulations of the Commission promulgated
thereunder.
"Selling Expenses" shall mean all underwriting discounts,
selling commissions and stock transfer taxes applicable to the securities
registered by the Investors and all fees and disbursements of counsel for the
Investors.
1.2 Restrictions. The Common Shares shall not be sold, assigned,
transferred or pledged except in compliance with the provisions of the
Securities Act.
1.3 Restrictive Legend. Each certificate representing the Common
Shares and any other securities issued in respect of the Common Shares upon any
stock split, stock dividend, recapitalization, merger, consolidation or similar
event, shall (unless otherwise permitted by the provisions of Section 1.4 below)
be stamped or otherwise imprinted with legends in the following form (in
addition to any legend required under applicable state securities laws):
THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")
OR ANY STATE SECURITIES LAWS OR ANY OTHER APPLICABLE SECURITIES LAW. NEITHER THE
SHARES OF COMMON STOCK
<PAGE> 3
EVIDENCED HEREBY NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE REOFFERED,
SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT
SUBJECT TO, SUCH REGISTRATION REQUIREMENTS.
The legend set forth above shall be removed by delivery of substitute
certificates without such legend, and any related stop transfer instructions
shall be lifted forthwith as soon as practicable after the Common Shares have
been registered under the Securities Act.
1.4 Registration on Form S-3.
Within 30 days after the closing of the transactions contemplated in the
Purchase Agreement, the Company shall file a single registration statement on
Form S-3 (or any comparable or successor form) for a public offering of the
Common Shares. The Company will as soon as practicable, use its reasonable
efforts to have such registration statement declared effective (including,
without limitation, the execution of an undertaking to file post-effective
amendments, appropriate qualification under applicable blue sky or other state
securities laws and appropriate compliance with applicable regulations issued
under the Securities Act and any other governmental requirements or regulations,
provided that the Investors will inform the Company in writing with respect to
(i) offers and sales in particular jurisdictions for purposes of blue sky
compliance and (ii) changes in the plan of distribution). The Company will keep
effective such registration statement on S-3 until the earlier of (a) May 5,
2000 and (b) the disposition of the Common Shares registered pursuant to the
plan of distribution set forth in such registration statement.
1.5 Expenses of Registration. All Registration Expenses incurred in
connection with the registration and sale of the Common Shares shall be borne by
the Company. All Selling Expenses and other expenses relating to the
registration and sale of the Common Shares and the fees and expenses of any
attorneys representing the Investors shall be borne by the Investors of such
securities pro rata on the basis of the number of Common Shares so registered.
1.6 Registration Procedures. In connection with the foregoing
registration, the Company will keep the Investors (by notification to the single
counsel designated by such Investors) advised in writing as to the initiation of
each registration, qualification and compliance and as to the completion
thereof. At its expense the Company will:
(a) Prepare and file with the Commission a registration
statement with respect to the Common Shares as set forth in Section 1.4;
(b) Furnish to the Investors promptly after filing a
reasonable number of copies of the registration statement and all amendments
thereto, preliminary prospectus, final prospectus and such other documents as
reasonably requested in order to facilitate the public offering of the Common
Shares;
<PAGE> 4
(c) Use its reasonable efforts to register or qualify the
Common Shares covered by the registration statement under the securities or blue
sky laws of such jurisdictions within the United States as any Investor shall
reasonably request in writing and to take all necessary action to keep such
registration or qualification effective for the applicable period specified in
Section 1.4 provided, however, that the Company shall not be required to qualify
to transact business as a foreign corporation in any jurisdiction in which it
would not otherwise be required to be so qualified or to take any action which
would subject it to general service of process in any such jurisdiction in which
it is not then so subject (except as may be required by the Securities Act);
(d) Immediately notify each Investor (by notifying the
single counsel for the Investors), at any time when a prospectus relating
thereto is required to be delivered under the Securities Act, of the happening
of any event as a result of which the prospectus contained in the registration
statement, as then in effect, includes an untrue statement of a material fact or
omits to state any material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances
then existing (in which case, the Company shall promptly provide such Investor
with revised or supplemental prospectuses and if so requested by the Company,
the Investor shall promptly take action to cease making any offers of Common
Shares until receipt and distribution of such revised or supplemental
prospectuses); and
(e) The Company shall promptly notify the Investors when the
registration statement is declared effective.
1.7 Indemnification.
(a) The Company will indemnify each Investor, each of its
officers and directors and partners, each person controlling such Investor
within the meaning of Section 15 of the Securities Act and each underwriter, on
behalf of which a registration, qualification or compliance has been effected
pursuant to this Agreement, and each person who controls any underwriter within
the meaning of Section 15 of the Securities Act, against all expenses, claims,
losses, damages or liabilities (or actions in respect thereof), including any of
the foregoing incurred in settlement of any litigation, commenced or threatened,
arising out of or based on any untrue statement (or alleged untrue statement) of
a material fact contained in any registration statement, prospectus, offering
circular or other document, or any amendment or supplement thereto, incident to
any such registration, qualification or compliance, or based on any omission (or
alleged omission) to state therein a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in
which they were made, not misleading, or any violation by the Company of any
rule or regulation promulgated under the Securities Act applicable to the
Company in connection with any such registration, qualification or compliance,
and the Company will reimburse each such Investor, each of its officers and
directors, and each person controlling such Investor, each such underwriter and
each person who controls any such underwriter, for any legal and any other
expenses reasonably incurred in connection with investigating, preparing or
defending any such claim, loss, damage, liability or action, provided that the
Company will not be liable in any such case to the extent that any such claim,
loss, damage, liability or expense arises out of or is based on any untrue
statement or
<PAGE> 5
omission or alleged untrue statement or omission, made in reliance upon and in
conformity with written information furnished to the Company by an instrument
duly executed by such Investor, controlling person or underwriter and stated to
be specifically for use therein.
(b) Each Investor will, if Common Shares held by such
Investor are included in the securities as to which such registration,
qualification or compliance is being effected, indemnify the Company, each of
its directors and officers, each underwriter, if any, of the Company's
securities covered by such a registration statement, each person who controls
the Company or such underwriter within the meaning of Section 15 of the
Securities Act, and each other such Investor, each of its officers and directors
and each person controlling such Investor within the meaning of Section 15 of
the Securities Act, against all claims, losses, damages and liabilities (or
actions in respect thereof) arising out of or based on any untrue statement (or
alleged untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other document, or any amendment or
supplement thereto, incident to any such registration, qualification or
compliance, or based on any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances in which they were made, not misleading,
and will reimburse the Company, such Investors, such directors, officers,
persons, underwriters or control persons for any legal or any other expenses
reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action, in each case to the extent, but only
to the extent, that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) was made in such registration statement,
prospectus, offering circular or other document, or any amendment or supplement
thereto, in reliance upon and in conformity with written information furnished
to the Company by an instrument duly executed by such Investor and stated to be
specifically for use therein; provided, however, that the liability of a
Investor for indemnification under this Section 1.7 shall not exceed the gross
proceeds from the offering received by such Investor.
(c) Each party entitled to indemnification under this
Section 1.7 (the "Indemnified Party") shall give written notice to the party
required to provide indemnification (the "Indemnifying Party") promptly after
such Indemnified Party has actual knowledge of any claim as to which indemnity
may be sought, and shall permit the Indemnifying Party to assume and control the
defense of any such claim or any litigation resulting therefrom, provided that
counsel for the Indemnifying Party, who shall conduct the defense of such claim
or litigation, shall be approved by the Indemnified Party (whose approval shall
not unreasonably be withheld), and the Indemnified Party may participate in such
defense at such party's expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 1.7 unless the failure
to give such notice is materially prejudicial to an Indemnifying Party's ability
to defend such action. No Indemnifying Party, in the defense of any such claim
or litigation, shall, except with the written consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party of a release from all liability in respect to such
claim or litigation.
<PAGE> 6
1.8 Information by Investor. The Investor or Investors of Common
Shares included in any registration shall furnish to the Company such
information regarding such Investor or Investors, the Common Shares held by them
and the distribution proposed by such Investor or Investors as shall be
reasonably necessary in order to ensure compliance with federal and applicable
state securities laws.
1.9 Transfer of Registration Rights. The rights to cause the Company
to register securities granted Investors hereof may not be assigned to any
transferee or assignee in connection with any transfer or assignment of the
Common Shares.
1.10 Inspection. The Company shall make reasonably available for
inspection by any Investor, any underwriter participating in any such
disposition of the Common Shares, if any, and any attorney, accountant or other
agent retained by any such Investor, or underwriter (together, the
"Inspectors"), at the offices where normally kept, during the Company's normal
business hours, all financial and other records, pertinent corporate documents
and properties of the Company and its subsidiaries as shall be reasonably
necessary to enable them to exercise any applicable due diligence
responsibilities, and cause the officers, directors and employees of the Company
and its subsidiaries to supply all relevant information in each case reasonably
requested by any such Inspector in connection with such registration statement.
1.11 Contribution. In order to provide for just and equitable
contribution in circumstances under which any of the indemnity provisions set
forth in this Agreement is for any reason held to be unavailable to the
indemnified parties although applicable in accordance with its terms, the
Company and the Investors shall contribute to the aggregate losses, liabilities,
claims, damages and expenses of the nature contemplated by such indemnity
agreement incurred by the Company and the Investors, as incurred; provided that
no person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person
that was not guilty of such fraudulent misrepresentation. As between the Company
and the Investors, such parties shall contribute to such aggregate losses,
liabilities, claims, damages and expenses of the nature contemplated by such
indemnity agreement in such proportion as shall be appropriate to reflect the
relative fault of the Company, on the one hand, and the Investors, on the other
hand, with respect to the statements or omissions which resulted in such loss,
liability, claim, damage or expense, or action in respect thereof, as well as
any other relevant equitable considerations. The relative fault of the Company,
on the one hand, and of the Investors, on the other hand, shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement
of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company, on the one hand, or by or on
behalf of the Investors, on the other, and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission. The Company and the Investors with respect to the Common
Shares agree that it would not be just and equitable if contribution pursuant to
this Agreement were to be determined by pro rata allocation or by any other
method of allocation that does not take into account the relevant equitable
considerations. For purposes of this Agreement, each affiliate of an Investor,
and each director, officer, employee, agent and person, if any, who controls an
Investor or such affiliate within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange
<PAGE> 7
Act shall have the same rights to contribution as such Investor, and each
director of the Company, each officer of the Company who signed the registration
statement, and each person, if any, who controls the Company within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have
the same rights to contribution as the Company.
1.12 No Inconsistent Agreements. The Company has not entered into nor
will the Company on or after the date of this Agreement enter into any agreement
which is inconsistent with the rights granted to the Investors with respect to
the Common Shares in this Agreement or otherwise conflicts with the provisions
hereof. The rights granted to the Investors hereunder do not in any way conflict
with and are not inconsistent with the rights granted to the holders of the
Company's other issued and outstanding securities under any such agreements.
1.13 Specific Enforcement. Without limiting the remedies available to
the Investors, the Company acknowledges that any failure by the Company to
comply with its obligations under this Agreement may result in material
irreparable injury to the Investors for which there is no adequate remedy at
law, that it would not be possible to measure damages for such injuries
precisely and that, in the event of any such failure, any Investor may obtain
such relief as may be required to specifically enforce the Company's obligations
under this Agreement.
Sincerely,
Laserscope
By: Dennis LaLumandiere
----------------------------
Title: Chief Financial Officer
-------------------------
Agreed and Accepted by:
Investor
- --------------------------------- -----------------------------------
Address
- --------------------------------- -----------------------------------
Name (print) Telephone Number
